<DOC>
	<DOCNO>NCT03000660</DOCNO>
	<brief_summary>This study determine safety , tolerability maximum tolerate dose Venetoclax ( ABT-199 ) dexamethasone relapse refractory amyloid light chain ( AL ) amyloidosis patient .</brief_summary>
	<brief_title>Trial Venetoclax ( ABT-199 ) Dexamethasone Relapsed Refractory Systemic AL Amyloidosis</brief_title>
	<detailed_description>The study conduct determine safety , tolerability maximum tolerate dose Venetoclax dexamethasone relapse refractory amyloid light chain ( AL ) amyloidosis patient . AL amyloidosis disease involve cell call plasma cell make antibody part immune system . These cell function way suppose start produce abnormal fragment antibody toxic body form amyloid . The antibody fragment call `` light chain . '' They cause damage organ , especially kidney , heart , skin , liver , lung . Researchers look way stop light chain form treat disease . Under circumstance , patient receive chemotherapy drug order manage disease . However , researcher know best treatment relapse AL amyloidosis , researcher test new drug new combination drug see work best least side effect . The researcher want find Venetoclax ( ABT-199 ) addition dexamethasone reduce eliminate AL amyloidosis plasma cell . In study , vary dos Venetoclax give determine maximum tolerated safe dose study . The researcher may also gain good understand whether Venetoclax dexamethasone counter plasma cell disease cause AL amyloidosis .</detailed_description>
	<mesh_term>Amyloidosis</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>Histologic diagnosis AL amyloidosis , confirm positive Congo red stained biopsy , evidence measurable clonal disease accord require active treatment Eastern Cooperative Oncology Group ( ECOG ) status 0 2 Relapsed refractory least 1 prior therapy AL amyloidosis , investigator 's opinion , require treatment . Participants history autologous stem cell transplantation must adequate blood count independent growth factor support recover transplantrelated toxicity least 100 day postautologous transplant . Less 30 % plasma cell bone marrow biopsy bone lesion hypercalcemia . The prescreening test CD138+ patient marrow plasma cell must show patient 's CD138+ plasma cell apoptosis ratio Venetoclax treat untreated cell great 1.4 . Objective , measurable organ involvement . Skin purpura , carpal tunnel syndrome , presence vascular amyloid bone marrow biopsy alone sufficient meet criterion `` symptomatic organ involvement '' . Patients may follow amyloidrelated organ involvement define : 1 . Renal : albuminuria high 0.5 g/day 24hour urine collection . 2 . Cardiac : involvement define presence mean leave ventricular wall thickness echocardiogram 12 mm absence history hypertension valvular heart disease , unexplained low voltage ( &lt; 0.5 mV ) electrocardiogram ; NTproBNP &gt; 332 ng/L CKD 1 2 patient BNP &gt; 100ng/L CKD3 . 3 . Hepatic : hepatomegaly physical examination alkaline phosphatase &gt; 1.5 X upper limit normal ( ULN ) . 4 . Autonomic peripheral neuropathy : base clinical history , autonomic dysfunction orthostasis , symptom nausea dysgeusia , gastric atony gastric empty scan , diarrhea constipation , abnormal sensory and/or motor finding neurologic examination . AL Amyloidosis Cardiac Risk stage I , II IIIa disease . Staging system define : NTproBNP cut &lt; 332 pg/mL troponin I cutoff &lt; 0.10 ng/mL threshold stage I , II III ; NTproBNP &lt; 8500 stage IIIa . 1 . Stage I , threshold ; 2 . Stage II , either troponin NTproBNP [ ] threshold ; 3 . Stage III , threshold ; 4 . Stage IIIa , threshold NTproBNP &lt; 8500 pg/ml . Clinical laboratory value specify first dose study drug : 1 . Echocardiographic ejection fraction &gt; 45 % within 28 day first dose study drug . 2 . Within 3 day first dose study drug : i. Platelet count &gt; 75 x 109/L ; ii . Neutrophil count &gt; 1.0 x 109/L ; iii . Total bilirubin &lt; 2 x ULN ; iv . Alkaline phosphatase &lt; 5 x ULN ; v. Alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) &lt; 3 x ULN ; vi . eGFR &gt; 30 mL/min/1.73 m2 Female patient postmenopausal least 1 year screen visit , OR surgically sterile , OR , childbearing potential , agree practice 2 effective method contraception , time , time signing inform consent 30 day last dose study drug , agree completely abstain heterosexual intercourse . Male patient , even surgically sterilize ( ie , status post vasectomy ) , agree practice effective barrier contraception entire study treatment period 30 day last dose study drug , OR agree completely abstain heterosexual intercourse . Voluntary write consent must give performance studyrelated procedure part standard medical care understanding consent may withdraw patient time without prejudice future medical care . Treatment investigational product within 28 day first dose study drug . Requirement concomitant chemotherapy , immunotherapy , radiotherapy , ancillary therapy consider investigational . Failure fully recover ( ie , &gt; Grade 1 toxicity ) effect prior chemotherapy regardless interval since last treatment . Active fungal infection require continue therapy . Cardiac system : 1 . QTc &gt; 470 millisecond ( msec ) 12 lead ECG obtain Screening period . If machine reading value , ECG review qualified reader confirm subsequent ECG . 2 . AL Amyloidosis Risk Stage IIIb disease . Stage IIIb define NTproBNP &gt; 8500 pg/mL troponin I &gt; 0.10 ng/mL . 3 . New York Heart Association ( NYHA ) classification III IV . 4 . Enzymedocumented myocardial infarction within 6 month enrollment . 5 . Chronic atrial fibrillation . 6 . Grade 2 3 atrioventricular ( AV ) block ( Mobitz , Type I permit ) . 7 . Supine systolic blood pressure &lt; 90 mmHg , symptomatic orthostatic hypotension , decrease systolic blood pressure stand &gt; 20 mm Hg spite treat orthostatic hypotension . 8 . History bleed diathesis currently receive treatment warfarin . Patients allow take aspirin . GI system : 1 . Severe diarrhea ( = Grade 3 ) controllable medication ( octreotide ) require administration total parenteral nutrition . 2 . Known GI disease GI procedure could interfere oral absorption tolerance study drug , include difficulty swallowing . Neurologic/ Social system : 1 . Patients &gt; Grade 2 peripheral neuropathy painful peripheral neuropathy clinical examination exclude . 2 . Previous ongoing psychiatric illness . 3 . Social situation would limit compliance study requirement . Systemic infection : 1 . Known human immunodeficiency virus ( HIV ) positive . 2 . Known hepatitis B surface antigenpositive know active hepatitis C infection . 3 . Uncontrolled infection require systemic antibiotic . Clinically overt multiple myeloma ( bone marrow plasma cell &gt; 30 % ) bone lesion hypercalcemia . Patients nonAL amyloidosis . Presence uncontrolled autoimmune hemolytic anemia thrombocytopenia , active malignancy exception nonmelanoma skin cancer , cervical cancer , treat earlystage prostate cancer provide prostatespecific antigen within normal limit , completely resect carcinoma situ . Female patient lactate pregnant . Major surgery within 14 day first dose study drug . Patients take required take follow agent CYP3A inhibitor : Amiodarone , Erythromycin , Fluconazole , Itraconazole , Ketoconazole , Miconazole , Diltiazem , Verapamil , Amprenavir , Fosamprenavir , Clarithromycin , Telithromycin , Nefazodone , Atazanavir , Darunavir , Indinavir , Lopinavir , Nelfinavir , Ritonavir , Saquinavir , Tipranavir .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Amyloidosis</keyword>
	<keyword>AL Amyloidosis</keyword>
	<keyword>Amyloid Light Chain Amylodosis</keyword>
	<keyword>ABT-199</keyword>
	<keyword>Venetoclax</keyword>
</DOC>